ABIONYX Pharma Presents Its “raison d'être” & States in Its Articles of Association: "To Develop Innovative Therapies in...
16 Giugno 2021 - 6:27PM
Business Wire
- Remobilizing of all employees, suppliers and shareholders
around the common objective of developing innovative
therapies
- The embodiment of a fundamental responsibility towards
patients, waiting for solutions in the rarest diseases
Regulatory News:
ABIONYX Pharma (FR0012616852 - ABNX - PEA PME
eligible), a new generation biotech company dedicated to the
discovery and development of innovative therapies for patients,
today announces that its “raison d’être” has been unanimously
approved by all shareholders represented at the last General
Meeting on June 11, 2021, and will now be included in the company's
articles of association.
This “raison d'être” will enlighten the company's future
strategic choices and long-term guidance at the heart of the public
health, economic and societal challenges of today and tomorrow.
A clear and strong commitment to an ESG approach for a
strategic model that creates even more positive impacts in
healthcare
Committed to an ESG approach, ABIONYX Pharma affirms its
willingness to move towards a strategic model that creates even
more positive impact for all its stakeholders.
The “raison d'être”, co-constructed with its collaborators and
stakeholders, which is "to develop innovative therapies in
indications with no effective or existing treatment, even the
rarest ones, for the benefit of patients" is the coherent and
conscious outcome of all the developments carried out by ABIONYX
Pharma over the last two years. Following an in-depth review of the
high-potential products in development in the company's portfolio,
the advanced and solid innovation skills of its employees, and the
increasingly positive impact on all of its stakeholders (patients,
physicians, hospitals and caregivers, suppliers, shareholders,
etc.), the company has been able to assess the positive effects of
the innovative development of one of its products, CER-001 :
- first in an ultra-rare renal disease within
the framework of a compassionate use thanks to nominative Temporary
Use Authorizations,
- then in a Phase II clinical trial in a
disease affecting more than 2 million people worldwide in sepsis at
high risk of Acute Kidney Injury,
- finally, in the context of extending the
potential of the innovation to ophthalmological indications, the
result of an unprecedented decompartmentalization between medical
specialties such as nephrology and ophthalmology thanks to the
pleiotropic action of natural HDL.
This “raison d'être” marks the continuation of a very engaging
process for the company, but also the formalization of the strategy
initiated since 2019 by ABIONYX Pharma to accelerate its evolution
into a positive impact company.
A roadmap to build in the transition to health for the
greatest number
Having established its “raison d'être”, the company is now
developing a roadmap around :
- Health for the greatest number of people, because it is
important to contribute to the development of innovative therapies
that allow the treatment of as many patients as possible, even for
the rarest diseases.
- Production of biomedicines in France, because it guarantees
control of the complex and strategic CER-001 biomanufacturing value
chain for Europe, in compliance with some of the most demanding
environmental and social conditions in the world.
- The socio-economic impact, because the commercial, financial
and human activity of ABIONYX Pharma generates an impact on
society, the economy and the environment.
The definition of the “raison d'être” marks the company's
willingness to become a committed company by developing a new
generation biotech business model that is inseparable from an
ambition to have a positive impact on the health of the greatest
number of people, for example through biomedicines such as
bio-HDL.
About ABIONYX Pharma
ABIONYX Pharma is a new generation biotech company that aims to
contribute to health through innovative therapies in indications
where there is no effective or existing treatment, even the rarest
ones. Thanks to its partners in research, medicine,
biopharmaceuticals and shareholding, the company innovates on a
daily basis to propose drugs for the treatment of renal and
ophthalmological diseases, or new HDL vectors used for targeted
drug delivery.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210616005803/en/
NewCap Investor relations Louis-Victor Delouvrier
abionyx@newcap.eu +33 (0)1 44 71 98 53
NewCap Media relations Nicolas Merigeau abionyx@newcap.eu
+33 (0)1 44 71 94 98
Grafico Azioni Abionyx Pharma (EU:ABNX)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Abionyx Pharma (EU:ABNX)
Storico
Da Apr 2023 a Apr 2024